FDA approves first generic Atacand
Sandoz has become the first company to gain the FDA approval to produce a generic version of Atacand (candesartan cilexetil), the popular heart drug that generated an estimated 120 million in domestic sales last year.
Sandoz has become the first company to gain FDA approval to produce a generic version of Atacand (candesartan cilexetil), the popular heart drug that generated an estimated $120 million in domestic sales last year.
“Sandoz is proud to be the first generic company to market this important generic treatment option to patients in the US,” said Don DeGolyer, president of Sandoz US. “The launch of candesartan further expands our offering of high-quality, affordable cardiology medicines.”
Candesartan cilexetil tablets are used to treat heart failure in some adults and hypertension in adults and children aged 1 to 17 years.
Sandoz’s generic candesartan cilexetil tablets will be available in 4-mg, 8-mg, 16-mg, and 32-mg strength tablets.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
